Cost-effectiveness of romosozumab for the treatment of postmenopausal women with osteoporosis at high risk of fracture in Belgium

Evelien Gielen,Martina Aldvén,John A. Kanis,Fredrik Borgström,Emmanuelle Senior,Damon Willems
DOI: https://doi.org/10.1007/s00198-024-07043-2
2024-04-04
Osteoporosis International
Abstract:This study evaluated the cost-effectiveness of sequential treatment with romosozumab-to-alendronate compared to alendronate monotherapy and teriparatide-to-alendronate, in postmenopausal osteoporotic women from a Belgian healthcare perspective. Romosozumab-to-alendronate was found to be cost-effective compared to alendronate monotherapy and dominant compared to teriparatide-to-alendronate for osteoporotic women at high risk of fracture in Belgium.
endocrinology & metabolism
What problem does this paper attempt to address?